Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
WARNING: This is the ONLY official Ourlyard store in Canada
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
Reductions in caloric intake are found across all body mass index (BMI) categories
This type doesnt provide any added vitamins or minerals
Taking the Next Step Insulin resistance sits at the core of many metabolic problems, and addressing it can produce improvements that ripple across multiple aspects of health
monitor glucose) - GLP-1 + MK-677 (competing appetite effects
US$ 27.57
US$ 25.47
US$ 20.18
US$ 22.32
